Is Cyclerion Therapeutics, Inc. (CYCN) a Buy, Sell, or Hold?
NASDAQ : CYCN
Cyclerion Therapeutics, Inc.
$3.8 USD
$0.1 (2.84%)
- Volume
- 5.54K
- Average Volume
- 53.31K
- Market Capitalization
- $16.46M
- P/E Ratio
- -2.68
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $8.48
- Year Low
- $1.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.80
Company Overview
NASDAQ
Regina Graul
Biotechnology
Healthcare
CYCN
1
US
USD
Liquidity Metrics
0.00
1.80
1.80
1.65
0.00
Sales & Valuation
$2.07M
8.26
2.35
-4.59
-0.85
Profitability
-$1.09
-$3.53M
-264.73%
-264.73%
-62.10%
-62.03%
P/E Metrics
-2.68
0.05
0.05
Analyst Price Target & Rating
2/5
2 Analysts
%
Financial Health Scores
-41.24
1/9
$1.38M
$8.5M
$1.71M
-$5.28M
Key Metrics (TTM)
$12.72M
6.38
-2.41
1.80
-62.10%
-99.03%
-34.95%
-23.08%
-229 days
Company Executives
| Name | Title |
|---|---|
| Regina Graul | Chief Executive Officer, President & Director |
| Rhonda Chicko | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered ... systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.
Frequently Asked Questions
-
What is the current Cyclerion Therapeutics, Inc. (CYCN) stock price?
-
Cyclerion Therapeutics, Inc.(NASDAQ:CYCN) stock price is $3.8 in the last trading session. During the trading session, CYCN stock reached the peak price of $8.48 while $1.027 was the lowest point it dropped to. The percentage change in CYCN stock occurred in the recent session was 2.84% while the dollar amount for the price change in CYCN stock was $0.1.
-
CYCN's industry and sector of operation?
-
The NASDAQ listed CYCN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CYCN?
-
Regina Graul | Chief Executive Officer, President & Director
Rhonda Chicko | Chief Financial Officer
|
|
| -
How many employees does CYCN have?
-
Number of CYCN employees currently stands at 1. CYCN operates from 245 First Street, Cambridge, MA 02142, US.
-
Link for CYCN official website?
-
Official Website of CYCN is: https://www.cyclerion.com
-
How do I contact CYCN?
-
CYCN could be contacted at phone #857 327 8778 and can also be accessed through its website. CYCN operates from 245 First Street, Cambridge, MA 02142, US.
-
How many shares of CYCN are traded daily?
-
The average number of CYCN shares traded daily for last 3 months was 53.31K.
-
What is the market cap of CYCN currently?
-
The market value of CYCN currently stands at $16.46M with its latest stock price at $3.8